By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BiondVax Pharmaceuticals 

Science Park, 14 Einstein Street
P.O. Box 4143
Ness Ziona    74140  Israel
Phone: 972-8-9302529 Fax: 972-8-9302531


Company News
European Investment Bank (EIB) Supports Late-Stage Development And Production Of BiondVax Pharmaceuticals’s Universal Flu Vaccine Candidate Under Horizon 2020 Initiative 6/19/2017 6:47:31 AM
BiondVax Pharmaceuticals Announces First Quarter 2017 Financial Results And Update 5/30/2017 8:22:53 AM
BiondVax Pharmaceuticals Announces Fourth Quarter And Full Year 2016 Financial Results And Update 4/28/2017 10:42:15 AM
BiondVax Pharmaceuticals Approved For Grant From Israel's Ministry Of Economy And Industry To Build Facility For Commercial Scale Production Of Its Universal Flu Vaccine 3/30/2017 7:47:49 AM
BiondVax Pharmaceuticals Publishes Regulatory Approval Strategy For Novel Universal Flu Vaccines In Future Virology Journal 3/13/2017 9:00:23 AM
BiondVax Pharmaceuticals Release: Back to the Future: Study Published In Vaccine Journal Indicates Company's Universal Flu Vaccine Candidate May Cover Strains Which Don't Yet Exist 1/12/2017 8:36:48 AM
BiondVax Pharmaceuticals Receives $US 2.8 Million Investment From Angels High Tech Investments Ltd. 1/3/2017 7:41:01 AM
BiondVax Pharmaceuticals Phase 2b Trial Preliminary Safety Results: The Universal Flu Vaccine Candidate Is Safe And Well Tolerated 11/29/2016 8:35:12 AM
BiondVax Pharmaceuticals Announces Third Quarter 2016 Financial Results And Update 11/28/2016 9:28:36 AM
Highly Pathogenic Bird Flu Spreading Across Europe And Asia; BiondVax Pharmaceuticals’s Universal Flu Vaccine Candidate Also Covers These Potential Pandemic Strains 11/22/2016 9:03:38 AM